This event will feature live presentations from executives of leading psychedelics companies addressing the various investment opportunities in psychedelic treatments for mental health disorders. The agenda highlights companies representing research, drug development, patient care delivery, integrated technology solutions, and patient support services.
To join the event, click the "Click here to join the April 27-28th KCSA Psychedelics Event" button above or click the name of any company below. You'll be prompted to sign in or sign up (if it's your first time) and then you'll be logged into the event.
Event Co-Sponsor
All presentation recordings are available to watch on-demand!
Field Trip Health Ltd.
NASDAQ: FTRP | TSX: FTRP
Country: Canada
Joseph del Moral, Co-Founder & CEO
Nathan Bryson, Chief Scientific Officer
Filament Health Corp
OTCQB: FLHLF | NEO: FH
Country: Canada
Ben Lightburn, CEO, Director & Co-Founder
HMNC Brain Health
Private
Country: Germany
Benedikt von Braunmuehl, CEO
Nir Naor, CFO
Hans Eriksson, Chief Clinical Development Officer
Mindset Pharma
OTCQB: MSSTF | CSE: MSET
Country: Canada
James Lanthier, CEO
Joseph Araujo, Chief Scientific Officer
Small Pharma Inc.
OTCQB: DMTTF | TSXV: DMT
Country: UK
Peter Rands, CEO, Founder
Dr. Carol Routledge, Chief Scientific and Medical Officer
